Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04464759 · ClinicalTrials.gov registry record · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
A Phase 1 study of Melanoma, sponsored by Ravi Amaravadi, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT04464759 is a Phase 1 study of Melanoma that is actively recruiting participants, run by Ravi Amaravadi, MD. The registered enrollment target is 94 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04464759, a Phase 1 study of Melanoma, is actively recruiting participants, sponsored by Ravi Amaravadi, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Hydroxychloroquine
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2020-10-21 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04464759
The ClinicalTrials.gov registry entry for NCT04464759 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (87% lower). The listed sponsor is Ravi Amaravadi, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04464759 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04464759 about?
NCT04464759 is a clinical study titled "A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma". This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
What is the current status of trial NCT04464759?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2020-10-21. Estimated completion is 2025-10-30.
What conditions does trial NCT04464759 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04464759?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04464759?
This trial is sponsored by Ravi Amaravadi, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04464759 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.